incretin mimetic
Pronunciation: IN-kreh-tin mi-MET-ik
A class of diabetes medications that mimic or enhance the action of incretin hormones to improve glucose control through multiple mechanisms.
Full Definition
Incretin mimetics are glucose-lowering medications that replicate or amplify the effects of endogenous incretin hormones, primarily glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These medications work through multiple mechanisms including glucose-dependent insulin secretion, suppression of glucagon release, slowing of gastric emptying, and promotion of satiety. The class includes GLP-1 receptor agonists (such as exenatide, liraglutide, and semaglutide) and DPP-4 inhibitors that prevent incretin degradation. Incretin mimetics offer significant benefits beyond glucose lowering, including weight loss with GLP-1 agonists and cardiovascular protection in certain high-risk populations. They have become cornerstone therapies in modern diabetes management.
Usage
Usage note: Hyphenate when used as an adjective. Broader category that includes both GLP-1 agonists and DPP-4 inhibitors.
In Context
- "The patient achieved excellent glucose control and significant weight loss with the incretin mimetic therapy." — Endocrinology clinic note
- "Incretin mimetics have transformed diabetes treatment by addressing multiple pathophysiologic defects simultaneously." — Diabetes therapeutics review